Medical Care
Global Natural Killer Cell Therapeutics Market Outlook, In‑Depth Analysis & Forecast to 2031
- Nov 18, 25
- ID: 573947
- Pages: 123
- Figures: 123
- Views: 8
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Natural Killer Cell Therapeutics market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Merck KGaA
Bristol-Myers Squibb Company
Glycostem
Sanofi
Cytovia Therapeutics
ImmunityBio, Inc.
Biohaven Pharmaceuticals
Fate Therapeutics
EMERcell
Phio Pharmaceuticals
Segment by Type
NK Cell Therapies
NK Cell Directed Antibodies
Segment by Application
Research & Academic Institutes
Hospitals
Specialty Clinics
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Natural Killer Cell Therapeutics study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Natural Killer Cell Therapeutics market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Merck KGaA
Bristol-Myers Squibb Company
Glycostem
Sanofi
Cytovia Therapeutics
ImmunityBio, Inc.
Biohaven Pharmaceuticals
Fate Therapeutics
EMERcell
Phio Pharmaceuticals
Segment by Type
NK Cell Therapies
NK Cell Directed Antibodies
Segment by Application
Research & Academic Institutes
Hospitals
Specialty Clinics
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Natural Killer Cell Therapeutics study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Natural Killer Cell Therapeutics: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Natural Killer Cell Therapeutics Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 NK Cell Therapies
1.2.3 NK Cell Directed Antibodies
1.3 Market Segmentation by Application
1.3.1 Global Natural Killer Cell Therapeutics Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Research & Academic Institutes
1.3.3 Hospitals
1.3.4 Specialty Clinics
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Natural Killer Cell Therapeutics Revenue Estimates and Forecasts 2020-2031
2.2 Global Natural Killer Cell Therapeutics Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Natural Killer Cell Therapeutics Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Natural Killer Cell Therapeutics Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 NK Cell Therapies Market Size by Players
3.3.2 NK Cell Directed Antibodies Market Size by Players
3.4 Global Natural Killer Cell Therapeutics Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Natural Killer Cell Therapeutics Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Natural Killer Cell Therapeutics Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Natural Killer Cell Therapeutics Market Size by Type (2020-2031)
6.4 North America Natural Killer Cell Therapeutics Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Natural Killer Cell Therapeutics Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Natural Killer Cell Therapeutics Market Size by Type (2020-2031)
7.4 Europe Natural Killer Cell Therapeutics Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Natural Killer Cell Therapeutics Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Natural Killer Cell Therapeutics Market Size by Type (2020-2031)
8.4 Asia-Pacific Natural Killer Cell Therapeutics Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Natural Killer Cell Therapeutics Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Natural Killer Cell Therapeutics Market Size by Type (2020-2031)
9.4 Central and South America Natural Killer Cell Therapeutics Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Natural Killer Cell Therapeutics Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Natural Killer Cell Therapeutics Market Size by Type (2020-2031)
10.4 Middle East and Africa Natural Killer Cell Therapeutics Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Natural Killer Cell Therapeutics Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Merck KGaA
11.1.1 Merck KGaA Corporation Information
11.1.2 Merck KGaA Business Overview
11.1.3 Merck KGaA Natural Killer Cell Therapeutics Product Features and Attributes
11.1.4 Merck KGaA Natural Killer Cell Therapeutics Revenue and Gross Margin (2020-2025)
11.1.5 Merck KGaA Natural Killer Cell Therapeutics Revenue by Product in 2024
11.1.6 Merck KGaA Natural Killer Cell Therapeutics Revenue by Application in 2024
11.1.7 Merck KGaA Natural Killer Cell Therapeutics Revenue by Geographic Area in 2024
11.1.8 Merck KGaA Natural Killer Cell Therapeutics SWOT Analysis
11.1.9 Merck KGaA Recent Developments
11.2 Bristol-Myers Squibb Company
11.2.1 Bristol-Myers Squibb Company Corporation Information
11.2.2 Bristol-Myers Squibb Company Business Overview
11.2.3 Bristol-Myers Squibb Company Natural Killer Cell Therapeutics Product Features and Attributes
11.2.4 Bristol-Myers Squibb Company Natural Killer Cell Therapeutics Revenue and Gross Margin (2020-2025)
11.2.5 Bristol-Myers Squibb Company Natural Killer Cell Therapeutics Revenue by Product in 2024
11.2.6 Bristol-Myers Squibb Company Natural Killer Cell Therapeutics Revenue by Application in 2024
11.2.7 Bristol-Myers Squibb Company Natural Killer Cell Therapeutics Revenue by Geographic Area in 2024
11.2.8 Bristol-Myers Squibb Company Natural Killer Cell Therapeutics SWOT Analysis
11.2.9 Bristol-Myers Squibb Company Recent Developments
11.3 Glycostem
11.3.1 Glycostem Corporation Information
11.3.2 Glycostem Business Overview
11.3.3 Glycostem Natural Killer Cell Therapeutics Product Features and Attributes
11.3.4 Glycostem Natural Killer Cell Therapeutics Revenue and Gross Margin (2020-2025)
11.3.5 Glycostem Natural Killer Cell Therapeutics Revenue by Product in 2024
11.3.6 Glycostem Natural Killer Cell Therapeutics Revenue by Application in 2024
11.3.7 Glycostem Natural Killer Cell Therapeutics Revenue by Geographic Area in 2024
11.3.8 Glycostem Natural Killer Cell Therapeutics SWOT Analysis
11.3.9 Glycostem Recent Developments
11.4 Sanofi
11.4.1 Sanofi Corporation Information
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Natural Killer Cell Therapeutics Product Features and Attributes
11.4.4 Sanofi Natural Killer Cell Therapeutics Revenue and Gross Margin (2020-2025)
11.4.5 Sanofi Natural Killer Cell Therapeutics Revenue by Product in 2024
11.4.6 Sanofi Natural Killer Cell Therapeutics Revenue by Application in 2024
11.4.7 Sanofi Natural Killer Cell Therapeutics Revenue by Geographic Area in 2024
11.4.8 Sanofi Natural Killer Cell Therapeutics SWOT Analysis
11.4.9 Sanofi Recent Developments
11.5 Cytovia Therapeutics
11.5.1 Cytovia Therapeutics Corporation Information
11.5.2 Cytovia Therapeutics Business Overview
11.5.3 Cytovia Therapeutics Natural Killer Cell Therapeutics Product Features and Attributes
11.5.4 Cytovia Therapeutics Natural Killer Cell Therapeutics Revenue and Gross Margin (2020-2025)
11.5.5 Cytovia Therapeutics Natural Killer Cell Therapeutics Revenue by Product in 2024
11.5.6 Cytovia Therapeutics Natural Killer Cell Therapeutics Revenue by Application in 2024
11.5.7 Cytovia Therapeutics Natural Killer Cell Therapeutics Revenue by Geographic Area in 2024
11.5.8 Cytovia Therapeutics Natural Killer Cell Therapeutics SWOT Analysis
11.5.9 Cytovia Therapeutics Recent Developments
11.6 ImmunityBio, Inc.
11.6.1 ImmunityBio, Inc. Corporation Information
11.6.2 ImmunityBio, Inc. Business Overview
11.6.3 ImmunityBio, Inc. Natural Killer Cell Therapeutics Product Features and Attributes
11.6.4 ImmunityBio, Inc. Natural Killer Cell Therapeutics Revenue and Gross Margin (2020-2025)
11.6.5 ImmunityBio, Inc. Recent Developments
11.7 Biohaven Pharmaceuticals
11.7.1 Biohaven Pharmaceuticals Corporation Information
11.7.2 Biohaven Pharmaceuticals Business Overview
11.7.3 Biohaven Pharmaceuticals Natural Killer Cell Therapeutics Product Features and Attributes
11.7.4 Biohaven Pharmaceuticals Natural Killer Cell Therapeutics Revenue and Gross Margin (2020-2025)
11.7.5 Biohaven Pharmaceuticals Recent Developments
11.8 Fate Therapeutics
11.8.1 Fate Therapeutics Corporation Information
11.8.2 Fate Therapeutics Business Overview
11.8.3 Fate Therapeutics Natural Killer Cell Therapeutics Product Features and Attributes
11.8.4 Fate Therapeutics Natural Killer Cell Therapeutics Revenue and Gross Margin (2020-2025)
11.8.5 Fate Therapeutics Recent Developments
11.9 EMERcell
11.9.1 EMERcell Corporation Information
11.9.2 EMERcell Business Overview
11.9.3 EMERcell Natural Killer Cell Therapeutics Product Features and Attributes
11.9.4 EMERcell Natural Killer Cell Therapeutics Revenue and Gross Margin (2020-2025)
11.9.5 EMERcell Recent Developments
11.10 Phio Pharmaceuticals
11.10.1 Phio Pharmaceuticals Corporation Information
11.10.2 Phio Pharmaceuticals Business Overview
11.10.3 Phio Pharmaceuticals Natural Killer Cell Therapeutics Product Features and Attributes
11.10.4 Phio Pharmaceuticals Natural Killer Cell Therapeutics Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
12 Natural Killer Cell TherapeuticsIndustry Chain Analysis
12.1 Natural Killer Cell Therapeutics Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Natural Killer Cell Therapeutics Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Natural Killer Cell Therapeutics Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Natural Killer Cell Therapeutics: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Natural Killer Cell Therapeutics Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 NK Cell Therapies
1.2.3 NK Cell Directed Antibodies
1.3 Market Segmentation by Application
1.3.1 Global Natural Killer Cell Therapeutics Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Research & Academic Institutes
1.3.3 Hospitals
1.3.4 Specialty Clinics
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Natural Killer Cell Therapeutics Revenue Estimates and Forecasts 2020-2031
2.2 Global Natural Killer Cell Therapeutics Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Natural Killer Cell Therapeutics Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Natural Killer Cell Therapeutics Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 NK Cell Therapies Market Size by Players
3.3.2 NK Cell Directed Antibodies Market Size by Players
3.4 Global Natural Killer Cell Therapeutics Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Natural Killer Cell Therapeutics Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Natural Killer Cell Therapeutics Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Natural Killer Cell Therapeutics Market Size by Type (2020-2031)
6.4 North America Natural Killer Cell Therapeutics Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Natural Killer Cell Therapeutics Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Natural Killer Cell Therapeutics Market Size by Type (2020-2031)
7.4 Europe Natural Killer Cell Therapeutics Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Natural Killer Cell Therapeutics Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Natural Killer Cell Therapeutics Market Size by Type (2020-2031)
8.4 Asia-Pacific Natural Killer Cell Therapeutics Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Natural Killer Cell Therapeutics Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Natural Killer Cell Therapeutics Market Size by Type (2020-2031)
9.4 Central and South America Natural Killer Cell Therapeutics Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Natural Killer Cell Therapeutics Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Natural Killer Cell Therapeutics Market Size by Type (2020-2031)
10.4 Middle East and Africa Natural Killer Cell Therapeutics Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Natural Killer Cell Therapeutics Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Merck KGaA
11.1.1 Merck KGaA Corporation Information
11.1.2 Merck KGaA Business Overview
11.1.3 Merck KGaA Natural Killer Cell Therapeutics Product Features and Attributes
11.1.4 Merck KGaA Natural Killer Cell Therapeutics Revenue and Gross Margin (2020-2025)
11.1.5 Merck KGaA Natural Killer Cell Therapeutics Revenue by Product in 2024
11.1.6 Merck KGaA Natural Killer Cell Therapeutics Revenue by Application in 2024
11.1.7 Merck KGaA Natural Killer Cell Therapeutics Revenue by Geographic Area in 2024
11.1.8 Merck KGaA Natural Killer Cell Therapeutics SWOT Analysis
11.1.9 Merck KGaA Recent Developments
11.2 Bristol-Myers Squibb Company
11.2.1 Bristol-Myers Squibb Company Corporation Information
11.2.2 Bristol-Myers Squibb Company Business Overview
11.2.3 Bristol-Myers Squibb Company Natural Killer Cell Therapeutics Product Features and Attributes
11.2.4 Bristol-Myers Squibb Company Natural Killer Cell Therapeutics Revenue and Gross Margin (2020-2025)
11.2.5 Bristol-Myers Squibb Company Natural Killer Cell Therapeutics Revenue by Product in 2024
11.2.6 Bristol-Myers Squibb Company Natural Killer Cell Therapeutics Revenue by Application in 2024
11.2.7 Bristol-Myers Squibb Company Natural Killer Cell Therapeutics Revenue by Geographic Area in 2024
11.2.8 Bristol-Myers Squibb Company Natural Killer Cell Therapeutics SWOT Analysis
11.2.9 Bristol-Myers Squibb Company Recent Developments
11.3 Glycostem
11.3.1 Glycostem Corporation Information
11.3.2 Glycostem Business Overview
11.3.3 Glycostem Natural Killer Cell Therapeutics Product Features and Attributes
11.3.4 Glycostem Natural Killer Cell Therapeutics Revenue and Gross Margin (2020-2025)
11.3.5 Glycostem Natural Killer Cell Therapeutics Revenue by Product in 2024
11.3.6 Glycostem Natural Killer Cell Therapeutics Revenue by Application in 2024
11.3.7 Glycostem Natural Killer Cell Therapeutics Revenue by Geographic Area in 2024
11.3.8 Glycostem Natural Killer Cell Therapeutics SWOT Analysis
11.3.9 Glycostem Recent Developments
11.4 Sanofi
11.4.1 Sanofi Corporation Information
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Natural Killer Cell Therapeutics Product Features and Attributes
11.4.4 Sanofi Natural Killer Cell Therapeutics Revenue and Gross Margin (2020-2025)
11.4.5 Sanofi Natural Killer Cell Therapeutics Revenue by Product in 2024
11.4.6 Sanofi Natural Killer Cell Therapeutics Revenue by Application in 2024
11.4.7 Sanofi Natural Killer Cell Therapeutics Revenue by Geographic Area in 2024
11.4.8 Sanofi Natural Killer Cell Therapeutics SWOT Analysis
11.4.9 Sanofi Recent Developments
11.5 Cytovia Therapeutics
11.5.1 Cytovia Therapeutics Corporation Information
11.5.2 Cytovia Therapeutics Business Overview
11.5.3 Cytovia Therapeutics Natural Killer Cell Therapeutics Product Features and Attributes
11.5.4 Cytovia Therapeutics Natural Killer Cell Therapeutics Revenue and Gross Margin (2020-2025)
11.5.5 Cytovia Therapeutics Natural Killer Cell Therapeutics Revenue by Product in 2024
11.5.6 Cytovia Therapeutics Natural Killer Cell Therapeutics Revenue by Application in 2024
11.5.7 Cytovia Therapeutics Natural Killer Cell Therapeutics Revenue by Geographic Area in 2024
11.5.8 Cytovia Therapeutics Natural Killer Cell Therapeutics SWOT Analysis
11.5.9 Cytovia Therapeutics Recent Developments
11.6 ImmunityBio, Inc.
11.6.1 ImmunityBio, Inc. Corporation Information
11.6.2 ImmunityBio, Inc. Business Overview
11.6.3 ImmunityBio, Inc. Natural Killer Cell Therapeutics Product Features and Attributes
11.6.4 ImmunityBio, Inc. Natural Killer Cell Therapeutics Revenue and Gross Margin (2020-2025)
11.6.5 ImmunityBio, Inc. Recent Developments
11.7 Biohaven Pharmaceuticals
11.7.1 Biohaven Pharmaceuticals Corporation Information
11.7.2 Biohaven Pharmaceuticals Business Overview
11.7.3 Biohaven Pharmaceuticals Natural Killer Cell Therapeutics Product Features and Attributes
11.7.4 Biohaven Pharmaceuticals Natural Killer Cell Therapeutics Revenue and Gross Margin (2020-2025)
11.7.5 Biohaven Pharmaceuticals Recent Developments
11.8 Fate Therapeutics
11.8.1 Fate Therapeutics Corporation Information
11.8.2 Fate Therapeutics Business Overview
11.8.3 Fate Therapeutics Natural Killer Cell Therapeutics Product Features and Attributes
11.8.4 Fate Therapeutics Natural Killer Cell Therapeutics Revenue and Gross Margin (2020-2025)
11.8.5 Fate Therapeutics Recent Developments
11.9 EMERcell
11.9.1 EMERcell Corporation Information
11.9.2 EMERcell Business Overview
11.9.3 EMERcell Natural Killer Cell Therapeutics Product Features and Attributes
11.9.4 EMERcell Natural Killer Cell Therapeutics Revenue and Gross Margin (2020-2025)
11.9.5 EMERcell Recent Developments
11.10 Phio Pharmaceuticals
11.10.1 Phio Pharmaceuticals Corporation Information
11.10.2 Phio Pharmaceuticals Business Overview
11.10.3 Phio Pharmaceuticals Natural Killer Cell Therapeutics Product Features and Attributes
11.10.4 Phio Pharmaceuticals Natural Killer Cell Therapeutics Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
12 Natural Killer Cell TherapeuticsIndustry Chain Analysis
12.1 Natural Killer Cell Therapeutics Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Natural Killer Cell Therapeutics Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Natural Killer Cell Therapeutics Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Natural Killer Cell Therapeutics Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Natural Killer Cell Therapeutics Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Natural Killer Cell Therapeutics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Natural Killer Cell Therapeutics Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Natural Killer Cell Therapeutics Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Natural Killer Cell Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Natural Killer Cell Therapeutics Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Natural Killer Cell Therapeutics by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Natural Killer Cell Therapeutics as of 2024)
Table 11. Global Natural Killer Cell Therapeutics Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Natural Killer Cell Therapeutics Companies Headquarters
Table 13. Global Natural Killer Cell Therapeutics Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Natural Killer Cell Therapeutics Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Natural Killer Cell Therapeutics Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Natural Killer Cell Therapeutics Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Natural Killer Cell Therapeutics Revenue by Application (2026-2031) & (US$ Million)
Table 21. Natural Killer Cell Therapeutics High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Natural Killer Cell Therapeutics Growth Accelerators and Market Barriers
Table 25. North America Natural Killer Cell Therapeutics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Natural Killer Cell Therapeutics Growth Accelerators and Market Barriers
Table 27. Europe Natural Killer Cell Therapeutics Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Natural Killer Cell Therapeutics Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Natural Killer Cell Therapeutics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Natural Killer Cell Therapeutics Investment Opportunities and Key Challenges
Table 31. Central and South America Natural Killer Cell Therapeutics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Natural Killer Cell Therapeutics Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Natural Killer Cell Therapeutics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Merck KGaA Corporation Information
Table 35. Merck KGaA Description and Major Businesses
Table 36. Merck KGaA Product Features and Attributes
Table 37. Merck KGaA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Merck KGaA Revenue Proportion by Product in 2024
Table 39. Merck KGaA Revenue Proportion by Application in 2024
Table 40. Merck KGaA Revenue Proportion by Geographic Area in 2024
Table 41. Merck KGaA Natural Killer Cell Therapeutics SWOT Analysis
Table 42. Merck KGaA Recent Developments
Table 43. Bristol-Myers Squibb Company Corporation Information
Table 44. Bristol-Myers Squibb Company Description and Major Businesses
Table 45. Bristol-Myers Squibb Company Product Features and Attributes
Table 46. Bristol-Myers Squibb Company Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Bristol-Myers Squibb Company Revenue Proportion by Product in 2024
Table 48. Bristol-Myers Squibb Company Revenue Proportion by Application in 2024
Table 49. Bristol-Myers Squibb Company Revenue Proportion by Geographic Area in 2024
Table 50. Bristol-Myers Squibb Company Natural Killer Cell Therapeutics SWOT Analysis
Table 51. Bristol-Myers Squibb Company Recent Developments
Table 52. Glycostem Corporation Information
Table 53. Glycostem Description and Major Businesses
Table 54. Glycostem Product Features and Attributes
Table 55. Glycostem Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Glycostem Revenue Proportion by Product in 2024
Table 57. Glycostem Revenue Proportion by Application in 2024
Table 58. Glycostem Revenue Proportion by Geographic Area in 2024
Table 59. Glycostem Natural Killer Cell Therapeutics SWOT Analysis
Table 60. Glycostem Recent Developments
Table 61. Sanofi Corporation Information
Table 62. Sanofi Description and Major Businesses
Table 63. Sanofi Product Features and Attributes
Table 64. Sanofi Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Sanofi Revenue Proportion by Product in 2024
Table 66. Sanofi Revenue Proportion by Application in 2024
Table 67. Sanofi Revenue Proportion by Geographic Area in 2024
Table 68. Sanofi Natural Killer Cell Therapeutics SWOT Analysis
Table 69. Sanofi Recent Developments
Table 70. Cytovia Therapeutics Corporation Information
Table 71. Cytovia Therapeutics Description and Major Businesses
Table 72. Cytovia Therapeutics Product Features and Attributes
Table 73. Cytovia Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Cytovia Therapeutics Revenue Proportion by Product in 2024
Table 75. Cytovia Therapeutics Revenue Proportion by Application in 2024
Table 76. Cytovia Therapeutics Revenue Proportion by Geographic Area in 2024
Table 77. Cytovia Therapeutics Natural Killer Cell Therapeutics SWOT Analysis
Table 78. Cytovia Therapeutics Recent Developments
Table 79. ImmunityBio, Inc. Corporation Information
Table 80. ImmunityBio, Inc. Description and Major Businesses
Table 81. ImmunityBio, Inc. Product Features and Attributes
Table 82. ImmunityBio, Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. ImmunityBio, Inc. Recent Developments
Table 84. Biohaven Pharmaceuticals Corporation Information
Table 85. Biohaven Pharmaceuticals Description and Major Businesses
Table 86. Biohaven Pharmaceuticals Product Features and Attributes
Table 87. Biohaven Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Biohaven Pharmaceuticals Recent Developments
Table 89. Fate Therapeutics Corporation Information
Table 90. Fate Therapeutics Description and Major Businesses
Table 91. Fate Therapeutics Product Features and Attributes
Table 92. Fate Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Fate Therapeutics Recent Developments
Table 94. EMERcell Corporation Information
Table 95. EMERcell Description and Major Businesses
Table 96. EMERcell Product Features and Attributes
Table 97. EMERcell Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. EMERcell Recent Developments
Table 99. Phio Pharmaceuticals Corporation Information
Table 100. Phio Pharmaceuticals Description and Major Businesses
Table 101. Phio Pharmaceuticals Product Features and Attributes
Table 102. Phio Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Phio Pharmaceuticals Recent Developments
Table 104. Raw Materials Key Suppliers
Table 105. Distributors List
Table 106. Market Trends and Market Evolution
Table 107. Market Drivers and Opportunities
Table 108. Market Challenges, Risks, and Restraints
Table 109. Research Programs/Design for This Report
Table 110. Key Data Information from Secondary Sources
Table 111. Key Data Information from Primary Sources
List of Figures
Figure 1. Natural Killer Cell Therapeutics Product Picture
Figure 2. Global Natural Killer Cell Therapeutics Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. NK Cell Therapies Product Picture
Figure 4. NK Cell Directed Antibodies Product Picture
Figure 5. Global Natural Killer Cell Therapeutics Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Research & Academic Institutes
Figure 7. Hospitals
Figure 8. Specialty Clinics
Figure 9. Natural Killer Cell Therapeutics Report Years Considered
Figure 10. Global Natural Killer Cell Therapeutics Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 12. Global Natural Killer Cell Therapeutics Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global Natural Killer Cell Therapeutics Revenue Market Share by Region (2020-2031)
Figure 14. Global Natural Killer Cell Therapeutics Revenue Market Share Ranking (2024)
Figure 15. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 16. NK Cell Therapies Revenue Market Share by Player in 2024
Figure 17. NK Cell Directed Antibodies Revenue Market Share by Player in 2024
Figure 18. Global Natural Killer Cell Therapeutics Revenue Market Share by Type (2020-2031)
Figure 19. Global Natural Killer Cell Therapeutics Revenue Market Share by Application (2020-2031)
Figure 20. North America Natural Killer Cell Therapeutics Revenue YoY (2020-2031) & (US$ Million)
Figure 21. North America Top 5 Players Natural Killer Cell Therapeutics Revenue (US$ Million) in 2024
Figure 22. North America Natural Killer Cell Therapeutics Revenue (US$ Million) by Type (2020 - 2031)
Figure 23. North America Natural Killer Cell Therapeutics Revenue (US$ Million) by Application (2020-2031)
Figure 24. US Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 25. Canada Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 26. Mexico Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 27. Europe Natural Killer Cell Therapeutics Revenue YoY (2020-2031) & (US$ Million)
Figure 28. Europe Top 5 Players Natural Killer Cell Therapeutics Revenue (US$ Million) in 2024
Figure 29. Europe Natural Killer Cell Therapeutics Revenue (US$ Million) by Type (2020-2031)
Figure 30. Europe Natural Killer Cell Therapeutics Revenue (US$ Million) by Application (2020-2031)
Figure 31. Germany Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 32. France Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 33. U.K. Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 34. Italy Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 35. Russia Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Natural Killer Cell Therapeutics Revenue YoY (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Top 8 Players Natural Killer Cell Therapeutics Revenue (US$ Million) in 2024
Figure 38. Asia-Pacific Natural Killer Cell Therapeutics Revenue (US$ Million) by Type (2020-2031)
Figure 39. Asia-Pacific Natural Killer Cell Therapeutics Revenue (US$ Million) by Application (2020-2031)
Figure 40. Indonesia Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 41. Japan Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 42. South Korea Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 43. Australia Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 44. India Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 45. Indonesia Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 46. Vietnam Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 47. Malaysia Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 48. Philippines Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 49. Singapore Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 50. Central and South America Natural Killer Cell Therapeutics Revenue YoY (2020-2031) & (US$ Million)
Figure 51. Central and South America Top 5 Players Natural Killer Cell Therapeutics Revenue (US$ Million) in 2024
Figure 52. Central and South America Natural Killer Cell Therapeutics Revenue (US$ Million) by Type (2020-2031)
Figure 53. Central and South America Natural Killer Cell Therapeutics Revenue (US$ Million) by Application (2020-2031)
Figure 54. Brazil Natural Killer Cell Therapeutics Revenue (2020-2025) & (US$ Million)
Figure 55. Argentina Natural Killer Cell Therapeutics Revenue (2020-2025) & (US$ Million)
Figure 56. Middle East and Africa Natural Killer Cell Therapeutics Revenue YoY (2020-2031) & (US$ Million)
Figure 57. Middle East and Africa Top 5 Players Natural Killer Cell Therapeutics Revenue (US$ Million) in 2024
Figure 58. South America Natural Killer Cell Therapeutics Revenue (US$ Million) by Type (2020-2031)
Figure 59. Middle East and Africa Natural Killer Cell Therapeutics Revenue (US$ Million) by Application (2020-2031)
Figure 60. GCC Countries Natural Killer Cell Therapeutics Revenue (2020-2025) & (US$ Million)
Figure 61. Israel Natural Killer Cell Therapeutics Revenue (2020-2025) & (US$ Million)
Figure 62. Egypt Natural Killer Cell Therapeutics Revenue (2020-2025) & (US$ Million)
Figure 63. South Africa Natural Killer Cell Therapeutics Revenue (2020-2025) & (US$ Million)
Figure 64. Natural Killer Cell Therapeutics Industry Chain Mapping
Figure 65. Channels of Distribution (Direct Vs Distribution)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Table 1. Global Natural Killer Cell Therapeutics Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Natural Killer Cell Therapeutics Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Natural Killer Cell Therapeutics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Natural Killer Cell Therapeutics Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Natural Killer Cell Therapeutics Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Natural Killer Cell Therapeutics Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Natural Killer Cell Therapeutics Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Natural Killer Cell Therapeutics by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Natural Killer Cell Therapeutics as of 2024)
Table 11. Global Natural Killer Cell Therapeutics Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Natural Killer Cell Therapeutics Companies Headquarters
Table 13. Global Natural Killer Cell Therapeutics Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Natural Killer Cell Therapeutics Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Natural Killer Cell Therapeutics Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Natural Killer Cell Therapeutics Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Natural Killer Cell Therapeutics Revenue by Application (2026-2031) & (US$ Million)
Table 21. Natural Killer Cell Therapeutics High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Natural Killer Cell Therapeutics Growth Accelerators and Market Barriers
Table 25. North America Natural Killer Cell Therapeutics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Natural Killer Cell Therapeutics Growth Accelerators and Market Barriers
Table 27. Europe Natural Killer Cell Therapeutics Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Natural Killer Cell Therapeutics Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Natural Killer Cell Therapeutics Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Natural Killer Cell Therapeutics Investment Opportunities and Key Challenges
Table 31. Central and South America Natural Killer Cell Therapeutics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Natural Killer Cell Therapeutics Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Natural Killer Cell Therapeutics Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Merck KGaA Corporation Information
Table 35. Merck KGaA Description and Major Businesses
Table 36. Merck KGaA Product Features and Attributes
Table 37. Merck KGaA Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Merck KGaA Revenue Proportion by Product in 2024
Table 39. Merck KGaA Revenue Proportion by Application in 2024
Table 40. Merck KGaA Revenue Proportion by Geographic Area in 2024
Table 41. Merck KGaA Natural Killer Cell Therapeutics SWOT Analysis
Table 42. Merck KGaA Recent Developments
Table 43. Bristol-Myers Squibb Company Corporation Information
Table 44. Bristol-Myers Squibb Company Description and Major Businesses
Table 45. Bristol-Myers Squibb Company Product Features and Attributes
Table 46. Bristol-Myers Squibb Company Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Bristol-Myers Squibb Company Revenue Proportion by Product in 2024
Table 48. Bristol-Myers Squibb Company Revenue Proportion by Application in 2024
Table 49. Bristol-Myers Squibb Company Revenue Proportion by Geographic Area in 2024
Table 50. Bristol-Myers Squibb Company Natural Killer Cell Therapeutics SWOT Analysis
Table 51. Bristol-Myers Squibb Company Recent Developments
Table 52. Glycostem Corporation Information
Table 53. Glycostem Description and Major Businesses
Table 54. Glycostem Product Features and Attributes
Table 55. Glycostem Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Glycostem Revenue Proportion by Product in 2024
Table 57. Glycostem Revenue Proportion by Application in 2024
Table 58. Glycostem Revenue Proportion by Geographic Area in 2024
Table 59. Glycostem Natural Killer Cell Therapeutics SWOT Analysis
Table 60. Glycostem Recent Developments
Table 61. Sanofi Corporation Information
Table 62. Sanofi Description and Major Businesses
Table 63. Sanofi Product Features and Attributes
Table 64. Sanofi Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Sanofi Revenue Proportion by Product in 2024
Table 66. Sanofi Revenue Proportion by Application in 2024
Table 67. Sanofi Revenue Proportion by Geographic Area in 2024
Table 68. Sanofi Natural Killer Cell Therapeutics SWOT Analysis
Table 69. Sanofi Recent Developments
Table 70. Cytovia Therapeutics Corporation Information
Table 71. Cytovia Therapeutics Description and Major Businesses
Table 72. Cytovia Therapeutics Product Features and Attributes
Table 73. Cytovia Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Cytovia Therapeutics Revenue Proportion by Product in 2024
Table 75. Cytovia Therapeutics Revenue Proportion by Application in 2024
Table 76. Cytovia Therapeutics Revenue Proportion by Geographic Area in 2024
Table 77. Cytovia Therapeutics Natural Killer Cell Therapeutics SWOT Analysis
Table 78. Cytovia Therapeutics Recent Developments
Table 79. ImmunityBio, Inc. Corporation Information
Table 80. ImmunityBio, Inc. Description and Major Businesses
Table 81. ImmunityBio, Inc. Product Features and Attributes
Table 82. ImmunityBio, Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. ImmunityBio, Inc. Recent Developments
Table 84. Biohaven Pharmaceuticals Corporation Information
Table 85. Biohaven Pharmaceuticals Description and Major Businesses
Table 86. Biohaven Pharmaceuticals Product Features and Attributes
Table 87. Biohaven Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Biohaven Pharmaceuticals Recent Developments
Table 89. Fate Therapeutics Corporation Information
Table 90. Fate Therapeutics Description and Major Businesses
Table 91. Fate Therapeutics Product Features and Attributes
Table 92. Fate Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Fate Therapeutics Recent Developments
Table 94. EMERcell Corporation Information
Table 95. EMERcell Description and Major Businesses
Table 96. EMERcell Product Features and Attributes
Table 97. EMERcell Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. EMERcell Recent Developments
Table 99. Phio Pharmaceuticals Corporation Information
Table 100. Phio Pharmaceuticals Description and Major Businesses
Table 101. Phio Pharmaceuticals Product Features and Attributes
Table 102. Phio Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Phio Pharmaceuticals Recent Developments
Table 104. Raw Materials Key Suppliers
Table 105. Distributors List
Table 106. Market Trends and Market Evolution
Table 107. Market Drivers and Opportunities
Table 108. Market Challenges, Risks, and Restraints
Table 109. Research Programs/Design for This Report
Table 110. Key Data Information from Secondary Sources
Table 111. Key Data Information from Primary Sources
List of Figures
Figure 1. Natural Killer Cell Therapeutics Product Picture
Figure 2. Global Natural Killer Cell Therapeutics Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. NK Cell Therapies Product Picture
Figure 4. NK Cell Directed Antibodies Product Picture
Figure 5. Global Natural Killer Cell Therapeutics Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Research & Academic Institutes
Figure 7. Hospitals
Figure 8. Specialty Clinics
Figure 9. Natural Killer Cell Therapeutics Report Years Considered
Figure 10. Global Natural Killer Cell Therapeutics Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 12. Global Natural Killer Cell Therapeutics Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global Natural Killer Cell Therapeutics Revenue Market Share by Region (2020-2031)
Figure 14. Global Natural Killer Cell Therapeutics Revenue Market Share Ranking (2024)
Figure 15. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 16. NK Cell Therapies Revenue Market Share by Player in 2024
Figure 17. NK Cell Directed Antibodies Revenue Market Share by Player in 2024
Figure 18. Global Natural Killer Cell Therapeutics Revenue Market Share by Type (2020-2031)
Figure 19. Global Natural Killer Cell Therapeutics Revenue Market Share by Application (2020-2031)
Figure 20. North America Natural Killer Cell Therapeutics Revenue YoY (2020-2031) & (US$ Million)
Figure 21. North America Top 5 Players Natural Killer Cell Therapeutics Revenue (US$ Million) in 2024
Figure 22. North America Natural Killer Cell Therapeutics Revenue (US$ Million) by Type (2020 - 2031)
Figure 23. North America Natural Killer Cell Therapeutics Revenue (US$ Million) by Application (2020-2031)
Figure 24. US Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 25. Canada Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 26. Mexico Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 27. Europe Natural Killer Cell Therapeutics Revenue YoY (2020-2031) & (US$ Million)
Figure 28. Europe Top 5 Players Natural Killer Cell Therapeutics Revenue (US$ Million) in 2024
Figure 29. Europe Natural Killer Cell Therapeutics Revenue (US$ Million) by Type (2020-2031)
Figure 30. Europe Natural Killer Cell Therapeutics Revenue (US$ Million) by Application (2020-2031)
Figure 31. Germany Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 32. France Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 33. U.K. Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 34. Italy Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 35. Russia Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific Natural Killer Cell Therapeutics Revenue YoY (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Top 8 Players Natural Killer Cell Therapeutics Revenue (US$ Million) in 2024
Figure 38. Asia-Pacific Natural Killer Cell Therapeutics Revenue (US$ Million) by Type (2020-2031)
Figure 39. Asia-Pacific Natural Killer Cell Therapeutics Revenue (US$ Million) by Application (2020-2031)
Figure 40. Indonesia Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 41. Japan Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 42. South Korea Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 43. Australia Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 44. India Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 45. Indonesia Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 46. Vietnam Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 47. Malaysia Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 48. Philippines Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 49. Singapore Natural Killer Cell Therapeutics Revenue (2020-2031) & (US$ Million)
Figure 50. Central and South America Natural Killer Cell Therapeutics Revenue YoY (2020-2031) & (US$ Million)
Figure 51. Central and South America Top 5 Players Natural Killer Cell Therapeutics Revenue (US$ Million) in 2024
Figure 52. Central and South America Natural Killer Cell Therapeutics Revenue (US$ Million) by Type (2020-2031)
Figure 53. Central and South America Natural Killer Cell Therapeutics Revenue (US$ Million) by Application (2020-2031)
Figure 54. Brazil Natural Killer Cell Therapeutics Revenue (2020-2025) & (US$ Million)
Figure 55. Argentina Natural Killer Cell Therapeutics Revenue (2020-2025) & (US$ Million)
Figure 56. Middle East and Africa Natural Killer Cell Therapeutics Revenue YoY (2020-2031) & (US$ Million)
Figure 57. Middle East and Africa Top 5 Players Natural Killer Cell Therapeutics Revenue (US$ Million) in 2024
Figure 58. South America Natural Killer Cell Therapeutics Revenue (US$ Million) by Type (2020-2031)
Figure 59. Middle East and Africa Natural Killer Cell Therapeutics Revenue (US$ Million) by Application (2020-2031)
Figure 60. GCC Countries Natural Killer Cell Therapeutics Revenue (2020-2025) & (US$ Million)
Figure 61. Israel Natural Killer Cell Therapeutics Revenue (2020-2025) & (US$ Million)
Figure 62. Egypt Natural Killer Cell Therapeutics Revenue (2020-2025) & (US$ Million)
Figure 63. South Africa Natural Killer Cell Therapeutics Revenue (2020-2025) & (US$ Million)
Figure 64. Natural Killer Cell Therapeutics Industry Chain Mapping
Figure 65. Channels of Distribution (Direct Vs Distribution)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Smart Grid Digital Substation Market Research Report 2026
Mar 17, 26
Global Photovoltaic Molded Case Circuit Breaker Market Research Report 2026
Mar 17, 26
Global Roll-Roll Automobile Business Market Research Report 2026
Mar 17, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232